CompletedPHASE1, PHASE2NCT01165996
Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome
Studying Acquired idiopathic sideroblastic anemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Case Comprehensive Cancer Center
- Principal Investigator
- Yogen SaunthararajahCleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
- Intervention
- flow cytometry(other)
- Enrollment
- 25 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2010 – 2012
Study locations (2)
- Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01165996 on ClinicalTrials.govOther trials for Acquired idiopathic sideroblastic anemia
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06270771OURA Ring Wearable Testing in MDS Patients: a Feasibility and Discovery Pilot StudySunnybrook Health Sciences Centre
- RECRUITINGNANCT04869683Biocollection in MyeloDysplastic Syndrome (P-MDS)University Hospital, Brest
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT00392353Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid LeukemiaNational Cancer Institute (NCI)
See all trials for Acquired idiopathic sideroblastic anemia →